

## Fournier`S Gangrene: The Importance of an Early Diagnosis

Guzmán Pérez Marta<sup>1</sup>; Solís García Del Pozo Julián<sup>2</sup>; Guzmán Martínez-Valls Pablo L<sup>3\*</sup>

<sup>1</sup>Internal Medicine Department, University Hospital of Albacete, Albacete, Spain.

<sup>2</sup>Internal Medicine Department, Infections Disease Section, University Hospital of Albacete, Albacete, Spain.

<sup>3</sup>Urology Department, Virgen de la Arrixaca University Clinical Hospital, Murcia, Spain.

### Abstract

**Introduction and objective:** Fournier's Gangrene (FG) is a necrotizing fasciitis that affects the external genitalia, perineum and perianal region, with occasional extension to the abdomen, lower limbs and even to the chest. The objective is to perform a descriptive analysis of the etiology and the risk factors of this disease, as well as to expose its diagnostic methods and therapeutic management based on the most recent scientific evidence of the latest years.

**Material and methods:** A narrative literature review has been made to identify the risk factors and the etiology, as well as the diagnostic methods and the therapeutic management.

**Results:** In 90% of the cases, initial lesions were identified, such as perianal pathology, genitourinary infections, malformations and skin lesions. FG is a polymicrobial necrotizing fasciitis. The predisposing factors are: Diabetes, obesity, neurological deficits, chronic alcoholism, malignant neoplasms, use of corticosteroids, malnutrition, HIV infection, peripheral vascular disease and hypertension. The diagnosis is mainly clinical. It begins with perianal or perineal pain, inflammation, erythema, edema, that progresses to necrosis, crackling, foul odor, and exudate. Imaging techniques are very important, especially the Computed Tomography (CT) scan. Treatment is based on surgery, with extensive debridement of necrotic tissue, washing and the use of broad-spectrum antibiotic therapy. It has a mortality rate around to 20-40%.

**Conclusion:** Early diagnosis is crucial for survival. It is eminently clinical and it relies on image tests such as the CT scan, which is the most sensitive and specific one. The three pillars of its treatment are: Hemodynamic support, empirical broad-spectrum antibiotic therapy and early surgical debridement.

**Keywords:** Fournier gangrene; Fasciitis; Genitalia.

**Manuscript Information:** Received: Apr 02, 2024; Accepted: May 01, 2024; Published: May 08, 2024

**Correspondance:** Pablo Luis Guzmán Martínez-Valls, Urology Department, Virgen de la Arrixaca University Clinical Hospital, Murcia, Spain, Ctra, Madrid-Cartagena, s/n. 30120 El Palmar, Murcia, Spain.

Tel: +34-616065288; Email: pabloguzmanmv@gmail.com

**Citation:** Marta GP, Julián SGDP, Pablo GMVL. Fournier`S Gangrene: The Importance of an Early Diagnosis. *J Surgery*. 2024; 4(1): 1164.

**Copyright:** © Pablo GMVL 2024. Content published in the journal follows creative common attribution license.

## Introduction

In 1764, Baurienne described an idiopathic and fatal necrotizing process that led to gangrene of the male genitalia [1]. However, Jean Alfred Fournier, a dermatologist expert in venereology, who described this pathology in more detail based on a series of 5 cases of male patients in 1883 [2]. Since then, understanding of the pathophysiology and etiology of the disease has been increasing. In the first descriptions, it was thought to be a pathology exclusive to adult men, although it was later found that it could affect women and children with a much lower prevalence [1].


Fournier's Gangrene (FG) is a rare and potentially fatal infectious disease, with a mortality rate between 20 and 40% [3]. It is a necrotizing fasciitis that affects the external genitalia, perineum and perianal region. The prevalence of this is around 0.02% of hospital admissions, with an incidence ratio of 1.6 cases per 100,000 men/year. The female/male ratio is 1:10, with males mainly affected in the age group of 40 to 50 years [4].

## Material and methods


A narrative literature review narrative has been carried out to identify the risk factors and etiology of FG, as well as to describe the diagnostic methods and therapeutic management of it. A has been carried out a bibliographic search in primary and secondary sources using as a search strategy: ("Fournier" [All Fields] or "suppliers" [All Fields], ("Fournier gangrene" [MeSH Terms] or "Fournier" [All Fields] and "gangrene" [All Fields]) or ("Fournier" [All Fields] and "gangrene" [All Fields]), including only studies in Spanish and English.




**Figure 2:** Fournier's gangrene in different evolutionary stages. **A.** Penile necrosis. **B.** Large scrotal edema with fluid drainage serosanguineous. **C.** Perineal and scrotal region with abundant exudate and sloughy tissue.



**Figure 1:** **A.** Perianal pathology. **B.** Emphysematous cystitis.



**Figure 3:** Axial CT sections showing the rise of gas interfacial on the abdominal wall.



**Figure 4:** Extensive surgical debridement of the penile, scrotal and perineal region.

**Table 1:** Evaluation and scoring system for Fournier's Gangrene: Fournier Gangrene Severity Index (FGSI).

Variable	Abnormal high values				Normal	Abnormal low values			
Score	4	3	2	1	0	1	2	3	4
Temperature (°C)	>41	39-40,9	-	38,5-38,4	36-38,4	34-35,9	32-33,9	30-31,9	<29,9
Heart rhythm (lpm)	>180	140-179	110-139	-	70-109	-	56-59	40-54	<39
Frequency respiratory (rmp)	>50	35-49	-	25-34	24-12	11;-10	9;-6	-	<5
Serum sodium (mmol/l)	>180	160-179	155-159	150-154	130-149	-	120-129	111-119	<110
Serum potassium (mmol/l)	>7	6-6,9	-	5,5-5,4	3,5-4	3-3,4	2,5-2,9	-	<2,5
Serum creatine (mg)	>3,5	2-3,4	1,5-1,9	-	0,6-1,4	-	<0,6	-	-
Hematocrit (%)	>60	-	50-59,9	46-49	30-45,9	-	20-29,9	-	<20
GB (total mm <sup>3</sup> /1.000)	>40	-	20-39,9	15-19,9	3-14,9	-	1-2,9	-	<1
Serum bicarbonate (mmol/l)	>52	41-51,9	-	32-40,9	22-31,9	-	18-21,9	15-17,9	<15

**Table 2:** Antibiotic therapy regimens recommended for the treatment of Fournier's Gangrene with mixed microbiological etiology.

Antibiotic	Dose
Piperacillin-Tazobactam+ Vancomycin	4,5 g c/6-8 h iv + 15 mg/kg c12 h
Imipenem-Cilastatina	1 g c/6-8 h iv
Meropenem	1g c/8 h iv
Ertapenem	1g /24h
Gentamicin	5mg/kg c/24h
Cefotaxime+Metronidazole+Clindamycin	2 g c/6h iv + 500 mg c/6h iv + 600-900 mg c/8h iv
Cefotaxima+Fosfomicin+Metronidazol	2g c/6 h iv + 5g c/8h iv +500 mg c/6h iv

## Results and discussion

### Etiology and common microorganisms

The cryptogenic nature of this illness has been reduced to a scarce 10% and inflammatory processes and local lesions have gained weight as the origin of FG. In 90% of cases, a clear triggering cause is identified. Of them, the most common are: perianal pathology (especially perianal abscesses, complex fistulas and anal fissures) (Figure 1A), genitourinary diseases (such as urethral injuries, whether in patients with a permanent urinary catheter or not), genitourinary infections (including postoperative genital infections) (Figure 1B), malformations (such as hypospadias), and skin lesions resulting from trauma or infectious processes [5].

FG is a polymicrobial or type 1 necrotizing fasciitis, with mixed flora of aerobic and anaerobic bacteria. Usually at least one anaerobic species is found such as *Bacteroides*, *Clostridium* or *Peptostreptococcus*. These are usually isolated in combination with some enterobacteria such as *E. Coli*, *Enterobacter*, *Klebsiella* or *Proteus* and one or more non-group A facultative anaerobic streptococci, such as *S. agalactiae* [4].

### Predisposing factors

There are several conditions related to the appearance of the disease. Diabetes mellitus has been identified as the most prevalent comorbidity in patients with Fournier's gangrene, since hyperglycemia directly affects the functions of chemotaxis, phagocytosis and cellular immune response [4]. In recent years and with the appearance of inhibitors of cotransporters sodium-glucose type II, cases of FG are described in patients who use them [6,7].

However, other predisposing factors have also been identified such as obesity, neurological deficit, chronic alcoholism, malignant neoplasms, chronic corticosteroid consumption, malnutrition, HIV infection, peripheral vascular disease and essential hypertension [4].

Laor and collaborators (cols.) described FGSI (Fournier Gangrene Severity Index, Table 1) [8] with the aim of evaluating the severity of FG. A score greater than or equal to 9 on this index is associated with a 75% probability of death, and a score less than 9 indicates a 78% probability of survival [9].

Amr Ehab El-Qushayri and cols. in the meta-analysis that they published in 2020 showed that there was a higher risk of mortality in patients with diabetes, cardiovascular disease, acute kidney failure and kidney disease [10]. However, no association was demonstrated between mortality and hypertension, lung disease, liver disease or tumor pathology [11].

Recently, in August 2023, A. Tufano and cols. published a systematic review and meta-analysis above a value to apply the systems Fournier's gangrene score on admission to predict mortality. For it, they used the FGSI, the simplified FGSI (SFGSI), and the Uladag FGSI (UFGSI). They concluding that high values are associated with a highest mortality, with the UFGSI being the most accurate [12].

### **Pathophysiology**

In FG there is usually an entry point in the skin. After the penetration of the germs, the infection is favored by the mentioned factors that generate an imbalance between the host's immunity and the virulence of the microorganisms. The production of enzymes such as collagenase, lecithinase and exotoxins, lead to rapid multiplication of microorganisms and the spread of the disease. Invading bacteria cause thrombosis in vessels found in the hypodermis, leading to tissue ischemia aggravated by edema. The decrease in oxygen in the tissues favors the proliferation of anaerobic bacteria with the consequent necrosis of the fascia [13].

### **Diagnostic evaluation**

The diagnostic is fundamentally clinical. It is a condition that is characterized because in most cases it begins with perianal or perineal pain, which seems disproportionately greater than the physical finding, accompanied by inflammation, erythema, edema or pruritus in the affected area.

During the first 24 hours it evolves to necrosis, crepitation, foul odor and exudate serosanguineous dark. Between the following 48 and 72 hours, the erythema takes blue-black color and evolves towards tissue necrosis (Figure 2). On the fourth or fifth day, gangrene is evident, there is a decrease in pain due to necrosis of the nerves and between the eighth and tenth day, the necrotic tissue is separated by a suppurative process from the adjacent tissues [14].

As for systemic manifestations, they are usually caused by deterioration of general condition, marked prostration, nausea and vomiting, progressing to hydroelectrolyte alterations, sepsis, shock and death.

In general, patients consult a doctor once the necrotic lesions have been established, although in some cases they consult before this evolutionary stage [15].

The diagnosis can be supported by radiological imaging techniques (Figure 3). Among them is the simple genitourinary radiograph, which can show a thickening of the soft tissues associated with a radiolucent pattern demonstrating interstitial gas in the subcutaneous tissues, although it does not allow demonstrating fascial involvement. Genital ultrasound may show edema of the affected wall with diffuse hyperechogenic foci giving a typical dirty appearance due to subcutaneous emphysema, accompanied by reactive unilateral or bilateral hydrocele in males when

the scrotum and testicular sheaths are affected. The Computerized Tomography (CT) is the most sensitive and specific technique. The most frequently found finding is subcutaneous emphysema, which appears in 90% of cases as a granular hypodense area. Despite this being a usually present sign, we cannot rule out the diagnosis of FG when it does not exist. Additionally, CT can show the presence of subcutaneous collections and the extent of fascial damage, which could not be demonstrated with the other techniques [16].

For microbiological diagnosis, a sample must be taken from a representative area, in an adequate quantity, avoiding contamination of commensal flora and before administering antibiotic treatment [17]. Aspiration of purulent collections (deeper area) with a needle and syringe, biopsy and curettage are preferred to swabs. However, some studies have indicated that this last method is simpler, cheaper, non-invasive and useful for wounds [17]. The rapid and correct transport of the samples (transport means or capped syringe), as well as their proper processing, will be of great importance for the recovery of microorganisms, especially anaerobes [17]. Gram stains and cultures should be done in aerobic and anaerobic media [17].

### **Treatment**

Currently, treatment is based on initial surgery, with extensive debridement and resections (Figure 4), removing all necrotic or infected tissue associated with profuse lavage and the use of broad-spectrum antibiotic therapy (Table 2) [18,19].

It has been proven that tissue gangrene can reach dizzying speeds of up to 2-3cm/h, so rapid diagnosis and early initiation of surgical treatment is vital [18].

Furthermore, it has been shown that the degree of internal necrosis involvement is often much greater than that suggested by external signs, and therefore, repeated debridement is usually necessary in order to reduce mortality [20].

An important part of FG therapy is good local hygiene (wound dressings should be changed at least twice a day) [21]. In addition, it is not uncommon for an orchiectomy, cystostomy, or diverting colostomy to be required, depending on the extent of the infection, if it has reached the scrotum, perineal area, or lower abdominal wall, respectively [22].

In case of septic shock, replacement with abundant fluids, crystalloids and colloids if necessary, in addition to perfusion with vasopressors is essential [20,22,23].

Recommended antibiotic therapy (Table 2) would involve a broad-spectrum penicillin or third-generation cephalosporin, gentamicin and metronidazole or clindamycin, although it should be adjusted and directed according to the results of microbiological cultures [20-23].

### **Conclusion**

Fournier's Gangrene is a necrotizing fasciitis that affects the external genitalia, perineum and perianal region, with eventual extension to the abdomen, lower limbs and even thorax. It is a rare pathology (1.6 cases per 100,000 men/year) but with a high mortality rate (20-40%).

The diagnosis is fundamentally clinical, based on complementary analytical, microbiological and radiological tests, with Computed Tomography (CT) being the most sensitive and specific imaging test for the diagnosis of this disease.

The three fundamental pillars of FG treatment are hemodynamic support of the patient, broad-spectrum empirical antibiotic therapy and early surgical debridement. It is a time-dependent disease. Early diagnosis is essential for urgent surgical debridement (<24h) in order to reduce the mortality rate. It is important to remember the need to carry out active post-surgical surveillance in case the patient's re-intervention is necessary.

Prevention and correction of risk factors in the population would help reduce the incidence of this disease, which is often unsuspected and whose result can be fatal.

#### Authors' Contribution and conflicts of interest

**Marta Guzman Perez:** Takes responsibility for the integrity of the data and the accuracy of the data. Study concept and design, drafting of the manuscript, critical review of the manuscript for important intellectual content.

**Julián Solis García del Pozo:** Study concept and design, drafting of the manuscript, critical review of the manuscript for important intellectual content.

**Pablo Luis Guzmán Martínez-Valls:** Study concept and design, drafting of the manuscript, critical review of the manuscript for important intellectual content.

All authors have read and approved the final version of the manuscript and declare that this manuscript is original and has not been edited or sent to another publication, nor is it in the process of being evaluated by any other scientific journal and declare that are free from any personal or commercial association that could imply a conflict of interest in connection with the article and they have respected the ethical principles of research.

#### References

1. Baurienne H. Sur une plaie contuse qui s'est terminée par le sphacèle de le scrotum. *J Med Chir Pharm.* 1764; 20: 251-253.
2. Fournier A. *Semaine Médical.* 1883; 2(3): 345-347.
3. Camargo L, García Perdomo H. Gangrena de Fournier: Revisión de factores determinantes de mortalidad. *Revista Chilena de Cirugía.* 2016; 68(3): 273-277.
4. Vargas T, Mora S, Zeledón A. Gangrena de Fournier: Generalidades. *Revista Médica Sinergia* 2019; 4(6): 100-107.
5. Montoya R, Izquierdo E, Pietricica BN, Pellicer E, Aguayo JL, et al. Análisis descriptivo de 20 casos y revisión de la bibliografía científica. *Actas Urológicas Españolas.* 2009; 33(8): 873-880.
6. Bersoff-Match SJ, Chamberlain C, Cao C, Kortepeter C, Chong WH. Fournier gangrene associated with sodium-glucose cotransporter-2 inhibitors: A review of spontaneous postmarketing cases. *Annals of Internal Medicine.* 2019; 170 (11): 764-769. doi: 10.7326/M19-0085.
7. Tran BA, Updike WH, Bullers K, Serag-Bolos E. Sodium-Glucose Cotransporter 2 Inhibitor Use Associated With Fournier's Gangrene: A Review of Case Reports and Spontaneous Post-Marketing Cases. *Clin Diabetes.* 2022; 40(1): 78-86. doi: 10.2337/cd21-0015.
8. Laor E, Palmer LS, Tolia BM, Reid RE, Winter HI. Outcome prediction in patients with Fournier's gangrene. *J Urol.* 1995; 154: 89-92.
9. Fernández DA, Guillén AH, Uribe J, Romero R, Gutierrez A. Etiología de la gangrena de Fournier como factor pronóstico de mortalidad: Análisis de 121 casos. *Actas Urológicas Españolas.* 2019; 43(10): 557-561.
10. El-Qushayri AE, Khalaf KM, Dahy A, Mahmoud AR, Benmelouka AY, et al. Fournier's gangrene mortality: A 17-year systematic review and meta-analysis. *Int J Infect Dis.* 2020; 92: 218-225.
11. Singh A, Ahmed K, Aydin A, Shamim M, Dasgupta P. Fournier's gangrene. A clinical review. *Archivo Italiano di Urologia e Andrologia.* 2016; 88(3): 157-164.
12. Tufano A, Dipinto P, Passaro F, Anceschi U, Franco G, et al. The Value of Fournier's Gangrene Scoring Systems on Admission to Predict Mortality: A Systematic Review and Meta-Analysis. *J Pers Med.* 2023; 13(9): 1283. doi: 10.3390/jpm13091283.
13. Zagli G, Cianchi G, Degl'innocenti S, et al. Treatment of Fournier's Gangrene with Combination of Vacuum-Assisted Closure Therapy, Hyperbaric Oxygen Therapy, and Protective Colostomy. *Case Rep Anesthesiol.* 2011; 2011: 430983. doi:10.1155/2011/430983.
14. Paty R, Smith AD. Gangrene and Fournier's Gangrene. *Urol Clin North Am.* 1992; 19(1): 149-162.
15. Gerber GS, Guss SP, Pielet RW. Fournier's gangrene secondary to intra-abdominal processes. *Urology.* 1994; 44(5): 779-82.
16. Levenson RB, Singh AK, Novelline RA. Fournier gangrene: role of imaging. *Radiographics.* 2008; 28(2): 519-28.
17. Porras L, Sáenz A, Calderon P, Gijón J. Infecciones de piel y partes blandas, en *Protocolos Enfermedades Infecciosas de la Sociedad Española de Medicina Interna.* 2009.
18. Fajdic J, Bukovic D, Hrgovic Z, Habek M, Gugic D, et al. Management of Fournier's gangrene- report of 7 cases and review of the literature. *Eur J Med Res.* 2007; 12: 169-172.
19. Hsu H, Li CM, Sun TB, Cheng LF, Chien SH. Unilateral gracilis myofasciocutaneous advancement flap for single stage reconstruction of scrotal and perineal defects. *J Plast Reconstr Aesthet Surg.* 2007; 60: 1055-1059.
20. Bonkat G, Bartoletti R, Bruyeres F, Cai T, Köves B, et al. European Association of Urology. Guidelines on Urological Infections 2023.
21. Kuzaka B, Wróblewska M, Borkowski T, Kawecki D, Kuzaka P, et al. Fournier's gangrene: Clinical presentation of 13 cases. *Med Sci Monit.* 2018; 24: 548-555.
22. Misiakos E, Bagias G, Patapis P, Sotiropoulos D, Kanavidis P, et al. Current concepts in the management of necrotizing fasciitis. *Front Surg.* 2014; 29(1): 00036.
23. Barquero Argüello M. Las Bases de la Gangrena de Fournier. *Revista Médica de Costa Rica y Centroamérica.* 2016; 73(619): 343-346.